Published in Postgrad Med on November 01, 2010
Neurocognitive performance in children and adolescents with bipolar disorder: a review. Eur Child Adolesc Psychiatry (2011) 1.44
Exercise and physical activity in mental disorders: clinical and experimental evidence. J Prev Med Public Health (2013) 1.29
The effects of physical exercise in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.11
Exercise and physical activity in mental disorders. Eur Arch Psychiatry Clin Neurosci (2011) 0.98
A brief review of exercise, bipolar disorder, and mechanistic pathways. Front Psychol (2015) 0.82
Animal models of bipolar mania: The past, present and future. Neuroscience (2015) 0.78
Stochastic resonance activity influences serum tryptophan metabolism in healthy human subjects. Int J Tryptophan Res (2011) 0.75
Bipolar Depression and Cognitive Impairment: Shared Mechanisms and New Treatment Avenues. Psychiatr Clin North Am (2015) 0.75
Effects of acute aerobic exercise on neural correlates of attention and inhibition in adolescents with bipolar disorder. Transl Psychiatry (2016) 0.75
On the search of new treatment strategies in patients with affective disorders. Eur Arch Psychiatry Clin Neurosci (2017) 0.75
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord (2009) 3.56
Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord (2012) 3.01
Comorbid somatic illnesses in patients with severe mental disorders: clinical, policy, and research challenges. J Clin Psychiatry (2008) 2.86
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord (2009) 2.17
Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am J Psychiatry (2007) 2.15
Novel investigational drugs targeting IL-6 signaling for the treatment of depression. Expert Opin Investig Drugs (2015) 2.07
A cohort study of the prevalence and impact of comorbid medical conditions in pediatric bipolar disorder. J Clin Psychiatry (2010) 1.79
Inflammation and the phenomenology, pathophysiology, comorbidity, and treatment of bipolar disorder: a systematic review of the literature. J Clin Psychiatry (2009) 1.70
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and select comorbid medical conditions. Ann Clin Psychiatry (2012) 1.64
Volumetric neuroimaging investigations in mood disorders: bipolar disorder versus major depressive disorder. Bipolar Disord (2008) 1.49
Incidence and costs of cardiometabolic conditions in patients with schizophrenia treated with antipsychotic medications. Clin Schizophr Relat Psychoses (2010) 1.44
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. Bipolar Disord (2006) 1.43
Is the cerebellum relevant in the circuitry of neuropsychiatric disorders? J Psychiatry Neurosci (2005) 1.35
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry (2007) 1.34
The CANMAT task force recommendations for the management of patients with mood disorders and comorbid anxiety disorders. Ann Clin Psychiatry (2012) 1.18
Predictors of nonresponse to cognitive behavioural therapy or venlafaxine using glucose metabolism in major depressive disorder. J Psychiatry Neurosci (2009) 1.16
Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr Diab Rep (2009) 1.16
Predictors of self-reported antidepressant adherence. Behav Med (2007) 1.16
Bipolar disorder and metabolic syndrome: an international perspective. J Affect Disord (2010) 1.07
The impact of obesity on quality of life. Best Pract Res Clin Endocrinol Metab (2013) 1.04
Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother (2012) 0.98
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. J Clin Psychiatry (2002) 0.95
The neurobiology of the EEG biomarker as a predictor of treatment response in depression. Neuropharmacology (2012) 0.95
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders. Ann Clin Psychiatry (2012) 0.95
Mood disorders and obesity: understanding inflammation as a pathophysiological nexus. Neuromolecular Med (2010) 0.95
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder. Ann Clin Psychiatry (2012) 0.95
Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet (2006) 0.95
The CANMAT task force recommendations for the management of patients with mood disorders and comorbid medical conditions: diagnostic, assessment, and treatment principles. Ann Clin Psychiatry (2012) 0.94
Major Depressive Disorder and Bipolar Disorder Predispose Youth to Accelerated Atherosclerosis and Early Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation (2015) 0.93
Differentiating bipolar disorders from major depressive disorders: treatment implications. Ann Clin Psychiatry (2007) 0.92
The effect of tumor necrosis factor antagonists on mood and mental health-associated quality of life: novel hypothesis-driven treatments for bipolar depression? Neurotoxicology (2009) 0.91
Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res (2012) 0.89
What Are the Implications of the STAR*D Trial for Primary Care? A Review and Synthesis. Prim Care Companion J Clin Psychiatry (2008) 0.89
The integrative management of treatment-resistant depression: a comprehensive review and perspectives. Psychother Psychosom (2014) 0.87
Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother (2011) 0.87
Relationship between regional brain metabolism, illness severity and age in depressed subjects. Psychiatry Res (2007) 0.86
The effect of bariatric surgery on psychiatric course among patients with bipolar disorder. Bipolar Disord (2013) 0.86
Effects of doxycycline on depressive-like behavior in mice after lipopolysaccharide (LPS) administration. J Psychiatr Res (2013) 0.86
Exercise and bipolar disorder: a review of neurobiological mediators. Neuromolecular Med (2009) 0.86
Long-acting risperidone: a review of its role in the treatment of bipolar disorder. Adv Ther (2009) 0.86
Neurocognitive-genetic and neuroimaging-genetic research paradigms in schizophrenia and bipolar disorder. J Neural Transm (Vienna) (2011) 0.86
Frequency and correlates of gambling problems in outpatients with major depressive disorder and bipolar disorder. Can J Psychiatry (2010) 0.86
Crosstalk between metabolic and neuropsychiatric disorders. F1000 Biol Rep (2012) 0.86
The association between childhood adversity and components of metabolic syndrome in adults with mood disorders: results from the international mood disorders collaborative project. Int J Psychiatry Med (2012) 0.85
Adverse events in children and adolescents treated with antipsychotic medications. Hum Psychopharmacol (2008) 0.85
Beyond pharmacotherapy: understanding the links between obesity and chronic mental illness. Can J Psychiatry (2012) 0.85
Assessing the prevalence of depression among individuals with diabetes in a Medicaid managed-care program. Int J Psychiatry Med (2008) 0.85
Towards a multifactorial approach for prediction of bipolar disorder in at risk populations. J Affect Disord (2012) 0.85
Prevalence and treatment of depression in children and adolescents with sickle cell disease: a retrospective cohort study. Prim Care Companion CNS Disord (2011) 0.85
An approach to managing depression. Defining and measuring outcomes. Can Fam Physician (2004) 0.84
Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. Expert Opin Drug Saf (2015) 0.84
Relation between cigarette smoking and cognitive function in euthymic individuals with bipolar disorder. Pharmacol Biochem Behav (2008) 0.84
Potential roles of zinc in the pathophysiology and treatment of major depressive disorder. Neurosci Biobehav Rev (2013) 0.83
Neural response to emotional stimuli associated with successful antidepressant treatment and behavioral activation. J Affect Disord (2013) 0.83
Neuroimaging approaches in mood disorders: technique and clinical implications. Ann Clin Psychiatry (2007) 0.83
Bipolar depression: trial-based insights to guide patient care. Dialogues Clin Neurosci (2008) 0.83
Correlates of metabolic abnormalities in bipolar I disorder at initiation of acute phase treatment. Psychiatry Investig (2009) 0.83
A New Perspective on the Anti-Suicide Effects With Ketamine Treatment: A Procognitive Effect. J Clin Psychopharmacol (2016) 0.82
Obesity and bipolar disorder: synergistic neurotoxic effects? Adv Ther (2013) 0.82
Inflammatory cytokines as an underlying mechanism of the comorbidity between bipolar disorder and migraine. Med Hypotheses (2012) 0.82
Body fat distribution and associations with metabolic and clinical characteristics in bipolar individuals. Eur Arch Psychiatry Clin Neurosci (2014) 0.82
Screening for bipolar disorder in the primary care: a Brazilian survey. J Affect Disord (2012) 0.81
Atypical antipsychotic tolerability and switching strategies in bipolar disorder. Expert Opin Pharmacother (2010) 0.81
Teratogenesis associated with antibipolar agents. Adv Ther (2009) 0.81
The rate of metabolic syndrome in euthymic Canadian individuals with bipolar I/II disorder. Adv Ther (2010) 0.81
Predicting treatment response in major depressive disorder: the impact of early symptomatic improvement. Can J Psychiatry (2012) 0.80
Endometrial cancer and antidepressants: A nationwide population-based study. Medicine (Baltimore) (2016) 0.80
Psychotropic drugs and renal failure: translating the evidence for clinical practice. Adv Ther (2009) 0.80
Tryptophan breakdown is increased in euthymic overweight individuals with bipolar disorder: a preliminary report. Bipolar Disord (2013) 0.79
Acetyl-L-carnitine and alpha-lipoic acid: possible neurotherapeutic agents for mood disorders? Expert Opin Investig Drugs (2008) 0.79
Admixture analysis of age at onset in major depressive disorder. Gen Hosp Psychiatry (2012) 0.79
Comorbidity in bipolar disorder: clinical and research opportunities. Bipolar Disord (2006) 0.79
The evolution of CANMAT Bipolar Disorder Guidelines: past, present, and future. Bipolar Disord (2013) 0.79
A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.79
Acute effects of single-dose olanzapine on metabolic, endocrine, and inflammatory markers in healthy controls. J Clin Psychopharmacol (2013) 0.79
Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog Neuropsychopharmacol Biol Psychiatry (2013) 0.78
Correlates of incident bipolar disorder in children and adolescents diagnosed with attention-deficit/hyperactivity disorder. J Clin Psychiatry (2014) 0.78
The risk of developing type 2 diabetes mellitus associated with psychotropic drug use in children and adolescents: a retrospective cohort analysis. Prim Care Companion CNS Disord (2012) 0.78
Aripiprazole for the maintenance treatment of bipolar disorder: a review of available evidence. Neuropsychiatr Dis Treat (2011) 0.78
Risk factors for incident major depressive disorder in children and adolescents with attention-deficit/hyperactivity disorder. Eur Child Adolesc Psychiatry (2014) 0.78
Prevention and reversal of ketamine-induced schizophrenia related behavior by minocycline in mice: Possible involvement of antioxidant and nitrergic pathways. J Psychopharmacol (2013) 0.78
Early switching strategies in antidepressant non-responders: current evidence and future research directions. CNS Drugs (2014) 0.78
Effects of alpha-lipoic acid in an animal model of mania induced by D-amphetamine. Bipolar Disord (2012) 0.78
The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid personality disorders. Ann Clin Psychiatry (2012) 0.78
Childhood treatment with psychotropic medication and development of comorbid medical conditions in adolescent-onset bipolar disorder. Hum Psychopharmacol (2011) 0.78
Early improvement as a predictor of acute treatment outcome in manic or mixed episodes in bipolar-1 disorder: a pooled, post hoc analysis from the asenapine development program. J Affect Disord (2013) 0.78
Economic grand rounds: economic costs of failure to monitor adverse effects of second-generation antipsychotics: an underestimated factor. Psychiatr Serv (2012) 0.77
Diabetes mellitus and disturbances in brain connectivity: a bidirectional relationship? Neuromolecular Med (2014) 0.77
Desvenlafaxine for the treatment of major depressive disorder. Expert Opin Pharmacother (2014) 0.77
Improving outcomes in patients with bipolar depression: a comprehensive review. J Clin Psychiatry (2015) 0.77
The mechanism, efficacy, and tolerability profile of agomelatine. Expert Opin Pharmacother (2013) 0.77
Discontinued psychiatric drugs in 2008. Expert Opin Investig Drugs (2009) 0.77
Fasting Blood Glucose and Depressive Mood among Patients with Mental Illness in a Medicaid Managed Care Program. Depress Res Treat (2011) 0.77
Clinical translation of neuroimaging research in mood disorders. Psychiatry (Edgmont) (2006) 0.77
Cardiovascular and neurological adverse events associated with antidepressant treatment in children and adolescents. J Child Neurol (2009) 0.77
Mood Stabilizers, Oxidative Stress and Antioxidative Defense in Euthymia of Bipolar Disorder. CNS Neurol Disord Drug Targets (2016) 0.76
Neurosurgical treatment of bipolar depression: defining treatment resistance and identifying surgical targets. Bipolar Disord (2010) 0.76
Invasive Cervical Cancer and Antidepressants: A Nationwide Population-Based Study. Medicine (Baltimore) (2015) 0.76